Amedisys Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Richard Ashworth

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.3%
Management average tenure	1.6yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO

Richard Ashworth (48 yo)

less than a year

Tenure

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Scott Ginn	Executive VP	6.5yrs	US$4.16m	0.067% $ 1.9m
Michael North	Chief Information Officer	7.4yrs	US$1.19m	0.033% $ 913.8k
Denise Bohnert	Chief Compliance Officer	4.6yrs	US$899.96k	no data
Nick Muscato	Chief Strategy Officer	no data	US$1.90m	0.0061% $ 170.8k
Richard Ashworth	President	less than a year	no data	0.34% $ 9.7m
Allyson Guidroz	Chief Accounting Officer & Principal Accounting Officer	less than a year	no data	0.0096% $ 269.4k
Pete Hartley	CTO & Senior VP of Business Operations Systems	no data	no data	no data
Jennifer Griffin	Senior VP	1.5yrs	no data	no data
Kendra Kimmons	VP of Marketing & Communications & Media Relations	no data	no data	no data
Adam Holton	Chief People Officer	1.6yrs	no data	0.00029% $ 8.1k
Francis Mayer	Senior Vice President of Development	no data	no data	no data

1.6yrs

Average Tenure

50yo

Average Age

Experienced Management: ADY's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Richard Ashworth	President	less than a year	no data	0.34% $ 9.7m
Paul Kusserow	Chairman	9.3yrs	US$4.08m	1.34% $ 37.4m
Bruce Perkins	Independent Director	9yrs	US$265.04k	0.054% $ 1.5m
Vickie Capps	Independent Director	4.4yrs	US$275.04k	0.0098% $ 275.1k
Molly Coye	Independent Director	4.4yrs	US$261.29k	0.0067% $ 189.3k
Julie Klapstein	Lead Independent DIrector	8yrs	US$277.54k	0.029% $ 808.1k
Jeffrey Rideout	Independent Director	8yrs	US$265.04k	0.0083% $ 233.6k
Teresa Kline	Independent Director	4.4yrs	US$265.04k	0.0098% $ 275.1k
Ivanetta Samuels	Independent Director	3.3yrs	US$250.04k	0.0030% $ 84.7k

4.4yrs

Average Tenure

62yo

Average Age

Experienced Board: ADY's board of directors are considered experienced (4.4 years average tenure).

Amedisys Management

Management criteria checks 1/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Recent updates

First quarter 2024 earnings released: EPS: US$0.44 (vs US$0.78 in 1Q 2023)

Full year 2023 earnings released: US$0.30 loss per share (vs US$3.65 profit in FY 2022)

Insufficient new directors

Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.79 in 3Q 2022)

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 18%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

First quarter 2023 earnings released: EPS: US$0.78 (vs US$0.97 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.65 (vs US$6.41 in FY 2021)

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Now 21% undervalued after recent price drop

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.79 (vs US$1.38 in 3Q 2021)

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

First quarter 2022 earnings released: EPS: US$0.97 (vs US$1.52 in 1Q 2021)

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently bought €125k worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Independent Director recently sold €1.8m worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

President & COO recently sold €64k worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold €420k worth of stock

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

New 90-day low: €195

Independent Director recently bought €215k worth of stock

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Revenue misses expectations

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

New 90-day high: €254

New 90-day high: €242

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

New 90-day high: €236

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

New 90-day high: €228

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day high: €214

New 90-day high - €204

New 90-day high - €200

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index